JP2017534254A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017534254A5 JP2017534254A5 JP2017513709A JP2017513709A JP2017534254A5 JP 2017534254 A5 JP2017534254 A5 JP 2017534254A5 JP 2017513709 A JP2017513709 A JP 2017513709A JP 2017513709 A JP2017513709 A JP 2017513709A JP 2017534254 A5 JP2017534254 A5 JP 2017534254A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- chain
- isolated human
- human antibody
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 23
- 239000003814 drug Substances 0.000 claims 16
- 229940079593 drug Drugs 0.000 claims 15
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 claims 10
- 102100039373 Membrane cofactor protein Human genes 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 101000717877 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 40S ribosomal protein S11-A Proteins 0.000 claims 7
- 101000717881 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 40S ribosomal protein S11-B Proteins 0.000 claims 7
- 101000643078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 40S ribosomal protein S9-A Proteins 0.000 claims 7
- 101000729607 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 40S ribosomal protein S9-B Proteins 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 5
- 210000004881 tumor cell Anatomy 0.000 claims 5
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 239000002502 liposome Substances 0.000 claims 4
- 208000023958 prostate neoplasm Diseases 0.000 claims 4
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims 3
- 231100000433 cytotoxic Toxicity 0.000 claims 3
- 230000001472 cytotoxic effect Effects 0.000 claims 3
- 150000002632 lipids Chemical class 0.000 claims 3
- 108010059074 monomethylauristatin F Proteins 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- WOWDZACBATWTAU-FEFUEGSOSA-N (2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-n-[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-n,3-dimethylbutanamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 WOWDZACBATWTAU-FEFUEGSOSA-N 0.000 claims 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims 2
- 101710112752 Cytotoxin Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 229940121849 Mitotic inhibitor Drugs 0.000 claims 2
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000000824 cytostatic agent Substances 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 239000002619 cytotoxin Substances 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 108010093470 monomethyl auristatin E Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010027452 Metastases to bone Diseases 0.000 claims 1
- 206010027457 Metastases to liver Diseases 0.000 claims 1
- 206010027459 Metastases to lymph nodes Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 239000012828 PI3K inhibitor Substances 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 claims 1
- 229960000853 abiraterone Drugs 0.000 claims 1
- 239000003080 antimitotic agent Substances 0.000 claims 1
- 108010044540 auristatin Proteins 0.000 claims 1
- 230000032823 cell division Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 229960001338 colchicine Drugs 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims 1
- 229930188854 dolastatin Natural products 0.000 claims 1
- 229960004671 enzalutamide Drugs 0.000 claims 1
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007928 intraperitoneal injection Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 229940124302 mTOR inhibitor Drugs 0.000 claims 1
- 230000034701 macropinocytosis Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- -1 radionuclides Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462049973P | 2014-09-12 | 2014-09-12 | |
| US62/049,973 | 2014-09-12 | ||
| PCT/US2015/049492 WO2016040683A1 (en) | 2014-09-12 | 2015-09-10 | Macropinocytosing human anti-cd46 antibodies and targeted cancer therapeutics |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020113065A Division JP7207753B2 (ja) | 2014-09-12 | 2020-06-30 | マクロピノサイトーシスによるヒト抗ｃｄ４６抗体及び標的とされた癌治療薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017534254A JP2017534254A (ja) | 2017-11-24 |
| JP2017534254A5 true JP2017534254A5 (https=) | 2018-10-18 |
| JP6730260B2 JP6730260B2 (ja) | 2020-07-29 |
Family
ID=55459583
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017513709A Active JP6730260B2 (ja) | 2014-09-12 | 2015-09-10 | マクロピノサイトーシスによるヒト抗ｃｄ４６抗体及び標的とされた癌治療薬 |
| JP2020113065A Active JP7207753B2 (ja) | 2014-09-12 | 2020-06-30 | マクロピノサイトーシスによるヒト抗ｃｄ４６抗体及び標的とされた癌治療薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020113065A Active JP7207753B2 (ja) | 2014-09-12 | 2020-06-30 | マクロピノサイトーシスによるヒト抗ｃｄ４６抗体及び標的とされた癌治療薬 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10533056B2 (https=) |
| EP (1) | EP3191524A4 (https=) |
| JP (2) | JP6730260B2 (https=) |
| KR (2) | KR102786695B1 (https=) |
| CN (2) | CN107135654B (https=) |
| AU (2) | AU2015315006B2 (https=) |
| CA (2) | CA2960282C (https=) |
| EA (1) | EA201790404A1 (https=) |
| IL (2) | IL251045B (https=) |
| MX (1) | MX2017003246A (https=) |
| WO (1) | WO2016040683A1 (https=) |
| ZA (1) | ZA201701545B (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| US10338069B2 (en) | 2010-04-12 | 2019-07-02 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
| US20130116404A1 (en) | 2011-11-08 | 2013-05-09 | Case Western Reserve University | Targeted non-invasive imaging probes of egfr expressing cells |
| US9782476B2 (en) | 2013-09-06 | 2017-10-10 | Academia Sinica | Human iNKT cell activation using glycolipids with altered glycosyl groups |
| US20150110814A1 (en) * | 2013-10-18 | 2015-04-23 | Psma Development Company, Llc | Combination therapies with psma ligand conjugates |
| CA2950423A1 (en) | 2014-05-27 | 2015-12-03 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
| KR102512592B1 (ko) * | 2014-05-27 | 2023-03-21 | 아카데미아 시니카 | 항-ｈｅｒ2 글리코항체 및 이의 용도 |
| KR20170003720A (ko) | 2014-05-27 | 2017-01-09 | 아카데미아 시니카 | 항-ｃｄ20 글리코항체 및 이의 용도 |
| CN106714829A (zh) | 2014-05-28 | 2017-05-24 | 中央研究院 | 抗TNF‑α醣抗体及其用途 |
| CN107135654B (zh) * | 2014-09-12 | 2021-10-29 | 加利福尼亚大学董事会 | 巨胞饮人类抗cd46抗体和靶向癌症疗法 |
| US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
| AU2015378564A1 (en) | 2015-01-24 | 2017-07-13 | Academia Sinica | Novel glycan conjugates and methods of use thereof |
| WO2017147542A2 (en) | 2016-02-26 | 2017-08-31 | Regeneron Pharmaceuticals, Inc. | Optimized transglutaminase site-specific antibody conjugation |
| EP3500594A4 (en) | 2016-08-22 | 2020-03-11 | Cho Pharma Inc. | ANTIBODIES, BINDING FRAGMENTS AND METHOD FOR USE |
| WO2018089829A1 (en) | 2016-11-10 | 2018-05-17 | Fortis Therapeutics, Inc. | Cd46-specific effector cells and uses thereof |
| ES3005158T3 (en) * | 2016-11-11 | 2025-03-14 | Univ California | Anti-cd46 antibodies and methods of use |
| JP2020535171A (ja) * | 2017-09-27 | 2020-12-03 | ターグイミューン セラピューティクス アーゲー | 去勢抵抗性前立腺癌 |
| WO2019183633A1 (en) | 2018-03-23 | 2019-09-26 | Case Western Reserve Univeristy | Psma targeted conjugate compounds and uses thereof |
| CN109535260B (zh) * | 2018-11-22 | 2021-08-10 | 东南大学 | 一种靶向cd46的人源嵌合抗原受体及其应用 |
| CA3182384A1 (en) * | 2020-06-18 | 2021-12-23 | Jay M. Short | Conditionally active anti-cd46 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| EP4192511A1 (en) * | 2020-08-07 | 2023-06-14 | Fortis Therapeutics, Inc. | Immunoconjugates targeting cd46 and methods of use thereof |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| EP4274613A4 (en) * | 2021-01-07 | 2024-12-18 | The Regents of the University of California | Modulation of cd46 cell surface expression and therapeutic use thereof |
| US20240058464A1 (en) * | 2021-01-07 | 2024-02-22 | Fortis Therapeutics, Inc. | Combination therapy with for46 for cancer |
| WO2022150512A1 (en) * | 2021-01-07 | 2022-07-14 | The Regents Of The University Of California | Modulation of cd46 cell surface marker in both androgen receptor-positive and negative cancer cells |
| CA3237590A1 (en) | 2021-11-09 | 2023-05-08 | James Basilion | Psma targeted conjugate compounds and uses thereof |
| CN116189759B (zh) * | 2023-03-13 | 2025-05-06 | 南京农业大学 | 一种群体感应先导化合物的虚拟筛选方法及应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2082277A1 (en) * | 1990-05-11 | 1991-11-12 | Damien F. J. Purcell | Cd46 variants |
| US20020115065A1 (en) * | 2000-08-28 | 2002-08-22 | Ton Logtenberg | Differentially expressed epitopes and uses thereof |
| EP1184458A1 (en) * | 2000-08-28 | 2002-03-06 | U-BISys B.V. | Differentially expressed CD46 epitopes, proteinaceous molecules capable of binding thereto, and uses thereof |
| WO2003032814A2 (en) | 2001-10-16 | 2003-04-24 | Raven Biotechnologies, Inc. | Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof |
| EP1482052A1 (en) * | 2003-05-27 | 2004-12-01 | Cytos Biotechnology AG | Modified polypeptides for targeting cell-entry of the adenoviruses of subtype B |
| JP2008534559A (ja) * | 2005-04-01 | 2008-08-28 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 血液凝固ｆｖｉｉｉ類似体 |
| CA2699394C (en) | 2007-09-17 | 2020-03-24 | The Regents Of The University Of California | Internalizing human monoclonal antibodies targeting prostate cancer cells in situ |
| BRPI0921433A2 (pt) * | 2008-10-31 | 2017-06-06 | Abbott Biotherapeutics Corp | uso de anticorpos anti-cs1 para o tratamento de linfomas raros |
| CA2810016A1 (en) * | 2010-09-03 | 2012-03-08 | Stem Centrx, Inc. | Novel modulators and methods of use |
| WO2012075111A1 (en) * | 2010-11-30 | 2012-06-07 | Novartis Ag | Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers |
| CN103889445A (zh) * | 2011-10-18 | 2014-06-25 | 德国杰特贝林生物制品有限公司 | 硫酸化糖胺聚糖用于改善因子viii的生物利用度的用途 |
| CN102863531A (zh) * | 2012-07-31 | 2013-01-09 | 张爱晖 | 一种抗cd20单克隆抗体及其制备方法和用途 |
| US9567402B2 (en) | 2013-03-14 | 2017-02-14 | The Regents Of The University Of California | Internalizing human monoclonal antibodies targeting prostate and other cancer cells |
| GB2513405A (en) * | 2013-04-26 | 2014-10-29 | Adc Biotechnology Ltd | Method of synthesising ADCs using affinity resins |
| EP2903744B1 (de) | 2014-03-21 | 2017-02-22 | Loesche GmbH | Verfahren und vorrichtung zum aufbereiten und trennen eines materials aus einem verbundenen mehrstoffsystem |
| CN107135654B (zh) | 2014-09-12 | 2021-10-29 | 加利福尼亚大学董事会 | 巨胞饮人类抗cd46抗体和靶向癌症疗法 |
| SMT202000285T1 (it) | 2015-11-10 | 2020-07-08 | Medimmune Llc | Molecole di legame specifiche per asct2 e loro usi |
| ES3005158T3 (en) | 2016-11-11 | 2025-03-14 | Univ California | Anti-cd46 antibodies and methods of use |
| US11939390B2 (en) | 2019-01-28 | 2024-03-26 | Sanofi-Aventis U.S. Llc | Methods of treating multiple myeloma |
| US20240058464A1 (en) | 2021-01-07 | 2024-02-22 | Fortis Therapeutics, Inc. | Combination therapy with for46 for cancer |
| WO2022150512A1 (en) | 2021-01-07 | 2022-07-14 | The Regents Of The University Of California | Modulation of cd46 cell surface marker in both androgen receptor-positive and negative cancer cells |
| EP4274613A4 (en) | 2021-01-07 | 2024-12-18 | The Regents of the University of California | Modulation of cd46 cell surface expression and therapeutic use thereof |
-
2015
- 2015-09-10 CN CN201580061138.5A patent/CN107135654B/zh active Active
- 2015-09-10 KR KR1020237024940A patent/KR102786695B1/ko active Active
- 2015-09-10 CA CA2960282A patent/CA2960282C/en active Active
- 2015-09-10 WO PCT/US2015/049492 patent/WO2016040683A1/en not_active Ceased
- 2015-09-10 KR KR1020177009569A patent/KR102559731B1/ko active Active
- 2015-09-10 US US15/508,059 patent/US10533056B2/en active Active
- 2015-09-10 EA EA201790404A patent/EA201790404A1/ru unknown
- 2015-09-10 CA CA3225295A patent/CA3225295A1/en active Pending
- 2015-09-10 EP EP15839357.9A patent/EP3191524A4/en active Pending
- 2015-09-10 AU AU2015315006A patent/AU2015315006B2/en active Active
- 2015-09-10 MX MX2017003246A patent/MX2017003246A/es unknown
- 2015-09-10 CN CN202111212538.5A patent/CN114106179B/zh active Active
- 2015-09-10 JP JP2017513709A patent/JP6730260B2/ja active Active
-
2017
- 2017-03-02 ZA ZA2017/01545A patent/ZA201701545B/en unknown
- 2017-03-09 IL IL251045A patent/IL251045B/en active IP Right Grant
-
2019
- 2019-11-21 US US16/691,417 patent/US12325755B2/en active Active
-
2020
- 2020-06-30 JP JP2020113065A patent/JP7207753B2/ja active Active
-
2021
- 2021-04-05 IL IL282077A patent/IL282077B/en unknown
- 2021-08-03 AU AU2021211989A patent/AU2021211989B2/en active Active
-
2025
- 2025-05-09 US US19/204,124 patent/US20250333533A1/en active Pending